<DOC>
	<DOCNO>NCT00431275</DOCNO>
	<brief_summary>This open-label , 2-arm study patient randomize receive either formulation use clinical trial formulation use drug become commercially available . The purpose study compare pharmacokinetics two formulation .</brief_summary>
	<brief_title>Study Compare Two Formulations CP-675,206 Monoclonal Antibody</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>Stage III Stage IV melanoma No evidence disease follow resection melanoma lesion Recovered prior surgical adjuvant treatmentrelated toxicity History chronic inflammatory autoimmune disease History inflammatory bowel disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>